Alembic Pharmaceuticals receives EIR from USFDA for oncology formulation facility

Alembic Pharmaceuticals receives EIR from USFDA for oncology formulation facility

By: IPP Bureau

Last updated : May 07, 2024 12:46 pm



With this, for all our USFDA facilities, EIRs are in place


Alembic Pharmaceuticals Limited has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) for the inspection carried out by them at our Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav from 28th February, 2024 to 8th March, 2024.

With this, for all our USFDA facilities, EIRs are in place.

Alembic Pharmaceuticals Limited USFDA

First Published : May 07, 2024 12:00 am